Skip to main content
Premium Trial:

Request an Annual Quote

Mirna Publishes Data on Delivery of miRNA Mimics

Premium

Mirna Therapeutics said this week that it has published data in Molecular Therapy showing that a neutral lipid emulsion can be used to systemically deliver tumor-suppressing microRNA mimics and reduce tumor burden in mouse lungs.

In the paper, researchers from Mirna and Yale University used a transgenic mouse model of lung cancer to show that intravenous administration of the lipid-formulated mimics of miR-34 and let-7 triggered an RNAi response in cancer cells and inhibited tumor growth.

“The successful therapeutic delivery of our miRNA mimics in a clinically relevant tumor model is an important milestone in bringing therapeutic miRNAs to the clinic,” Mirna President and CEO Paul Lammers said in a statement. “These data add to the increasing body of evidence that our technology can be applied in a therapeutic context.”

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more